AstraZeneca ends lung‑cancer trial of Volrustomig after it fails to beat Keytruda | EuroTelegraph

AstraZeneca halted its phase‑III study of the experimental drug Volrustomig in metastatic non‑small‑cell lung‑cancer patients with low PD‑L1 expression after the therapy showed no superiority over Keytruda when both were combined with chemotherapy.

AstraZeneca announced on 17 August 2026 that it is ending the advanced, phase‑III trial of its experimental lung‑cancer drug Volrustomig. The company said the drug did not demonstrate a larger benefit than the already‑available therapy Keytruda (pembrolizumab) when both were given together with chemotherapy.

The study targeted patients with metastatic non‑small‑cell lung cancer (NSCLC) whose tumours expressed low levels of the protein PD‑L1. Both arms of the trial received the standard chemotherapy backbone; one arm added Volrustomig, the other added Keytruda. According to a report in Handelsblatt – based on a Reuters release – the experimental drug “schnitt nicht besser ab als der verbreitete Wirkstoff Keytruda” (did not perform better than the widely used drug Keytruda).

The trial was a late‑stage, phase‑III oncology study, the most advanced stage before a potential regulatory filing. The independent expert panel that reviewed the data recommended stopping the study, a recommendation that AstraZeneca followed immediately.

Before the termination, Bloomberg‑surveyed analysts had projected roughly US$1.3 billion in revenue for Volrustomig by 2032. The same Bloomberg survey recorded Jefferies analyst Michael Leuchten describing the drug’s chances of success as “unlikely”. Both the revenue forecast and Leuchten’s comment are cited in the Handelsblatt article.

Because the drug will not move to market, the projected revenue figure is now a lost opportunity for the company. The forecast was based on the assumption that Volrustomig would achieve a market‑share advantage over Keytruda in the low‑PD‑L1 NSCLC segment.

AstraZeneca plc (ticker AZN, listed on the NYSE) is a UK‑based pharmaceutical group headquartered in Cambridge. The firm employs roughly 70,600 people and traces its origins to 1913. Its most recent Form 6‑K filings – dated 17 August 2026 and 19 August 2026 – confirm the announcement of the trial termination (SEC filings, company research). Pascal Soriot remains chief executive, as listed in the latest filing.

The company’s oncology portfolio includes several approved products, but the loss of Volrustomig removes a potential addition in the competitive NSCLC market. AstraZeneca has not disclosed how it will reallocate the resources tied to the trial.

Analysts had previously built revenue models around the $1.3 billion forecast. The termination eliminates that future cash‑flow, which could affect earnings guidance for the next few years. However, the company’s broader pipeline – which includes other lung‑cancer candidates and a range of oncology assets – may offset the impact over the longer term.

Investors should watch the company’s next earnings release for any revisions to its oncology outlook. The SEC filings do not yet contain a revised forecast, and the firm has not commented on the effect on its 2026‑2027 guidance.

From a clinical‑development perspective, the decision underscores the difficulty of demonstrating incremental benefit over established immunotherapies in NSCLC, especially in patient sub‑groups defined by low PD‑L1 expression.

Source: Handelsblatt (citing Reuters and Bloomberg), company SEC filings.

These gaps mean that market reaction will depend on forthcoming statements from AstraZeneca and any updated guidance in its next earnings release.

While the Volrustomig setback removes a potential revenue stream, AstraZeneca’s broader oncology strategy remains robust, with several late‑stage candidates in development. The company’s next public filing will likely outline how it intends to compensate for the lost opportunity and whether any other pipeline assets will be accelerated.

For investors and analysts, the key takeaway is that the $1.3 billion forecast is now off the table, and the firm’s future earnings will hinge on the performance of its remaining oncology portfolio and any new indications it brings to market.